Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
- PMID: 26923000
- PMCID: PMC4864964
- DOI: 10.1016/bs.ai.2015.12.003
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
Abstract
Despite recent clinical advances in immunotherapy, a fraction of cancer patients fails to respond to these interventions. Evidence from preclinical mouse models as well as clinical samples has provided evidence that the extent of activated T cell infiltration within the tumor microenvironment is associated with clinical response to immunotherapies including checkpoint blockade. Therefore, understanding the molecular mechanisms mediating the lack of T cell infiltration into the tumor microenvironment will be instrumental for the development of new therapeutic strategies to render those patients immunotherapy responsive. Recent data have suggested that major sources of intersubject heterogeneity include differences in somatic mutations in specific oncogene pathways between cancers of individual subjects and also environmental factors including commensal microbial composition. Successful identification of such causal factors should lead to new therapeutic approaches that may facilitate T cell entry into noninflamed tumors and expand the fraction of patients capable of responding to novel immunotherapies.
Keywords: Cancer immunotherapy; Microbiota; Tumor biology.
© 2016 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5. Science. 2015. PMID: 26541606 Free PMC article.
-
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.Clin Cancer Res. 2020 Aug 1;26(15):3901-3907. doi: 10.1158/1078-0432.CCR-19-1321. Epub 2020 Apr 24. Clin Cancer Res. 2020. PMID: 32332013 Free PMC article. Review.
-
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.Front Immunol. 2019 Sep 26;10:2293. doi: 10.3389/fimmu.2019.02293. eCollection 2019. Front Immunol. 2019. PMID: 31616443 Free PMC article. Review.
-
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10. Adv Immunol. 2016. PMID: 26922999 Free PMC article. Review.
-
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.Semin Oncol. 2015 Aug;42(4):663-71. doi: 10.1053/j.seminoncol.2015.05.011. Epub 2015 Jun 3. Semin Oncol. 2015. PMID: 26320069 Free PMC article. Review.
Cited by
-
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.Nat Rev Clin Oncol. 2023 Oct;20(10):697-715. doi: 10.1038/s41571-023-00803-9. Epub 2023 Jul 24. Nat Rev Clin Oncol. 2023. PMID: 37488231 Review.
-
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.Acta Neuropathol Commun. 2023 May 10;11(1):79. doi: 10.1186/s40478-023-01569-y. Acta Neuropathol Commun. 2023. PMID: 37165457 Free PMC article. Review.
-
Extracellular Vesicles in Breast Cancer: From Biology and Function to Clinical Diagnosis and Therapeutic Management.Int J Mol Sci. 2023 Apr 13;24(8):7208. doi: 10.3390/ijms24087208. Int J Mol Sci. 2023. PMID: 37108371 Free PMC article. Review.
-
The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.Front Immunol. 2023 Jan 16;13:1096551. doi: 10.3389/fimmu.2022.1096551. eCollection 2022. Front Immunol. 2023. PMID: 36726985 Free PMC article. Review.
-
Microbiome influencers of checkpoint blockade-associated toxicity.J Exp Med. 2023 Mar 6;220(3):e20220948. doi: 10.1084/jem.20220948. Epub 2023 Jan 9. J Exp Med. 2023. PMID: 36622383 Free PMC article.
References
-
- Abt MC, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. 2012;37:158–170. http://dx.doi.org/10.1016/j.immuni.2012.04.011. - DOI - PMC - PubMed
-
- Bak SP, et al. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor tolerized CD8 T cells. Journal of Immunology. 2012;189:1708–1716. http://dx.doi.org/10.4049/jimmunol.1201271. - DOI - PMC - PubMed
-
- Baldwin AS. Regulation of cell death and autophagy by IKK and NF-kappaB: Critical mechanisms in immune function and cancer. Immunological Reviews. 2012;246:327–345. http://dx.doi.org/10.1111/j.1600-065X.2012.01095.x. - DOI - PubMed
-
- Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25:6817–6830. http://dx.doi.org/10.1038/sj.onc.1209942. - DOI - PubMed
-
- Bedognetti D, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British Journal of Cancer. 2013;109:2412–2423. http://dx.doi.org/10.1038/bjc.2013.557. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources